We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cepmed Launches Online Personalized Medicine Portal

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cepmed Launches Online Personalized Medicine Portal"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Centre of Excellence in Personalized Medicine (Cepmed) has announced that they have launched a web-based Personalized Medicine Portal for Canadians and joined DNA Direct by Medco's Genomic Medicine Network (GMN).

Cepmed's Personalized Medicine Portal (Portal) provides information and decision making tools that will help patients understand how genetic testing can be used to inform treatment decisions and enable better communication between patients and providers.

The Portal, available at www.cepmed.com, provides information about access to specific genetic tests in each Province.

"Many of the stakeholders have told us that there is a dearth of reliable, evidence based information concerning personalized medicine tests. A centralized source of information about which tests exist, who should take them and how they should be interpreted is what we are offering through our partnership with DNA Direct by Medco. We believe this resource will contribute to improved patient outcomes and savings to the health care system." - Dr. Clarissa Desjardins - CEO, Cepmed.

According to the Personalized Medicine Coalition, there are more than 50 genetic tests currently available that can inform treatment decisions and drug therapy for a wide range of diseases.

With the availability of these tests, support and demand for personalized medicine is growing internationally. However, effective integration of personalized medicine into clinical care is challenging.

It is widely thought that effective adoption of personalized medicine will require the participation of informed and engaged patients and healthcare providers.

Cepmed plans to use the Portal as a key element of implementation studies in personalized medicine, collaborating with healthcare providers, patient organizations and the public to define how personalized medicine is best applied within the Canadian health care system.

These studies will be informed by Cepmed's participation in DNA Direct by Medco's GMN.

The GMN brings together leaders in personalized medicine and offers opportunities to establish multi-site studies in genomics, with a particular focus on real-world or implementation studies.

"We are excited about this opportunity to expand our Genomic Medicine Network to include a premier personalized medicine organization in Canada," said Joan Kennedy, President of DNA Direct by Medco.

Kennedy continued, "Cepmed will add a unique perspective and new types of collaboration opportunities across the network."